- Tariquidar
-
- $45.00 / 5mg
-
2026-03-13
- CAS:206873-63-4
- Min. Order:
- Purity: 98.46%
- Supply Ability: 10g
- Tariquidar
-
- $0.00 / 1KG
-
2025-04-04
- CAS:206873-63-4
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1Ton
- Tariquidar
-
- $15.00 / 1KG
-
2021-07-13
- CAS:206873-63-4
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | Tariquidar Basic information |
| Product Name: | Tariquidar | | Synonyms: | N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxy-phenyl]quinoline-3-carboxamide;Tariquidar;3-Quinolinecarboxamide, N-(2-(((4-(2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl)phenyl)amino)carbonyl)-4,5-dimethoxyphenyl)-;N-(2-((4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)carbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide;Unii-J58862dtvd;Xr 9576;Xr9576;N-[2-[N-[4-[2-(6,7-DiMethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl]carbaMoyl]-4,5-diMethoxyphenyl]quinoline-3-carboxaMide | | CAS: | 206873-63-4 | | MF: | C38H38N4O6 | | MW: | 646.73 | | EINECS: | | | Product Categories: | Inhibitors;Anti-cancer&immunity;Inhibitor | | Mol File: | 206873-63-4.mol |  |
| | Tariquidar Chemical Properties |
| Melting point | >190oC (dec.) | | Boiling point | 716.0±60.0 °C(Predicted) | | density | 1.276±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 10.67±0.70(Predicted) | | form | powder | | color | white to light brown | | InChIKey | LGGHDPFKSSRQNS-UHFFFAOYSA-N | | SMILES | N1C2C(=CC=CC=2)C=C(C(NC2=CC(OC)=C(OC)C=C2C(NC2=CC=C(CCN3CCC4=C(C3)C=C(OC)C(OC)=C4)C=C2)=O)=O)C=1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Aquatic Chronic 4 |
| | Tariquidar Usage And Synthesis |
| Description | Tariquidar is an anthranilic acid derivative that binds to P-glycoprotein (Kd = 5.1 nM) and inhibits transport activity. It inhibits transport of vinblastine and paclitaxel in multidrug resistant CHrB30 cells, increasing the steady state accumulation to non-P-glycoprotein-expressing multidrug sensitive cell levels (EC50 = 487 nM). Tariquidar also enhances the distribution of its substrates, increasing the amount of substrate entering the CNS. When administered at doses of 2 and 6.25 mg/kg in mice in combination with the peripherally-restricted opioid loperamide, the latency to paw withdrawal in a hot plate assay increases, indicating that loperamide is transported into the CNS. | | Uses | Tariquidar is a p-glycoprotein drug efflux pump inhibitor. Tariquidar inhibits the ATPase activity of P-glycoprotein, suggesting that the modulating effect is derived from the inhibition of substrate binding, inhibition of ATP hydrolysis or both.Tariquidar can be considered an ideal agent for testing the role of P-glycoprotein inhibition in cancer. | | Definition | ChEBI: Tariquidar is a member of benzamides. | | Biochem/physiol Actions | Specific inhibitor of MDR-1 (P-gp) | | target | P-glycoprotein | | References | [1] CATHERINE MARTIN. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein[J]. British Journal of Pharmacology, 2009, 128 2: 403-411. DOI: 10.1038/sj.bjp.0702807
[2] EDNA F CHOO. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier.[J]. Journal of Pharmacology and Experimental Therapeutics, 2006, 317 3: 1012-1018. DOI: 10.1124/jpet.105.099648 |
| | Tariquidar Preparation Products And Raw materials |
|